ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
25 avr. 2023 04h00 HE
|
AKAMPION
- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
12 avr. 2023 08h00 HE
|
AKAMPION
Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material...
Cancer Immunotherapy Market Size ($674 Bn by 2032 at 13.8% CAGR) Global Analysis by Market.us
28 mars 2023 07h40 HE
|
Market.Us
New York, March 28, 2023 (GLOBE NEWSWIRE) -- The Cancer Immunotherapy Market size accounted for USD 191 billion in 2022 and growth is estimated to accelerate at a CAGR of 13.8%, registering an...
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
23 mars 2023 07h55 HE
|
Evaxion Biotech
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
14 mars 2023 16h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
$120+ Billion Worldwide Immuno-Oncology Drugs Industry to 2032: Rising Number of Cancer Cases Drives the Market
13 mars 2023 12h33 HE
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
2023 Annual Next-Gen Immuno-Oncology Congress: Latest Updates in ADC's, mAb, BsAbs, Immune Checkpoint Inhibitors, and Cellular Therapy (Boston, MA, United States - June 22-23, 2023)
09 mars 2023 09h18 HE
|
Research and Markets
Dublin, March 09, 2023 (GLOBE NEWSWIRE) -- The "6th Annual Next-Gen Immuno-Oncology Conference" conference has been added to ResearchAndMarkets.com's offering. The 6th Annual Next Gen...
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
08 févr. 2023 09h00 HE
|
GeoVax, Inc.
Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
08 févr. 2023 06h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing...
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
07 févr. 2023 09h00 HE
|
GeoVax, Inc.
Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...